(NASDAQ: DSGN) Design Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.01%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Design Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast DSGN's revenue for 2029 to be $1,359,042,151, with the lowest DSGN revenue forecast at $1,359,042,151, and the highest DSGN revenue forecast at $1,359,042,151. On average, 1 Wall Street analysts forecast DSGN's revenue for 2030 to be $4,305,336,540, with the lowest DSGN revenue forecast at $4,305,336,540, and the highest DSGN revenue forecast at $4,305,336,540.
In 2031, DSGN is forecast to generate $7,519,011,401 in revenue, with the lowest revenue forecast at $7,519,011,401 and the highest revenue forecast at $7,519,011,401.